Allos' pralatrexate addresses a small population of about 5,000 patients with peripheral T-cell lymphoma (PTCL) in the U.S., but the drug would be the first approved to treat the disease. Today, PTCL patients are generally treated with a hodgepodge of chemotherapy regimens, none of which work very well.
I'd put pralatrexate peak sales in the U.S. between $200 million and $400 million (assuming premium pricing), with upside coming from expanded use in other cancers, including lung, if such use is justified by clinical data.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.